Erenumab
Summary
Risk. The use of amino acids, proteins, and peptides is not considered to have any environmental impact.
This summary information comes from fass.se. Equivalent information is provided in the assessment report.
Detailed information
Assessment report
Assessment report for Aimovig (erenumab) 31 May 2018 EMA/CHMP/413393/2018.
"Monoclonal antibodies such as AMG 334 (erenumab ed. remark) are catabolized to individual amino acids and/or small peptides by endogenous proteases and high molecular weight prevents intact urinary excretion. As such, excretion of active drug is not expected. For these reasons, exposure to concentrations of AMG 334 in the environment does not pose any concern."
Fass environmental information
Fass environmental information for Aimovig from Novartis (retrieved on 2025-06-27).
"The use of amino acids/peptides/proteins has been considered to result in an insignificant environmental impact. According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment. It is expected that any administered monoclonal antibody is completely metabolized and absorbed in the body. Any medicinal product that reaches water streams via spills during an application or after disposal of the unused drug, is expected to be very rapidly degraded and mineralized to CO2 by microbial activity."
Author: Health and Medical Care Administration, Region Stockholm